-
Alkermes Rises 3% Ahead Of Earnings (ALKS)
Thursday, May 12, 2011 - 2:56pm | 140Shares of biotechnology firm Alkermes (NASDAQ: ALKS) are rising on heavy volume ahead of the company's quarterly earnings report which is due out after the closing bell. Analysts have consensus EPS estimates calling for a loss of $0.14, which compares to a loss of $0.15 in the year ago period....
-
Hemispherx Biopharma's Ampligen Cited at Barcelona Vaccine & Active Immunotherapeutics Forum 2011
Thursday, May 12, 2011 - 1:06pm | 81Hemispherx Biopharma, Inc. (NYSE: HEB) today announced that Ampligen® will be featured in a discussion of "promising new discoveries that will direct step changes in efficacy of next generation cancer immunotherapies" in a round table discussion of Active Immunotherapy held at the Fira Palace in...
-
Options Brief: MannKind Corporation (MNKD)
Thursday, May 12, 2011 - 12:31pm | 74Shares of MannKind Corporation (NASDAQ: MNKD) are higher on the session by 5.15%, trading at $4.08. Overall put volume is now running at 2.79x the daily average, with 56% of all puts traded being purchases on the offer. 6,442 contracts have traded on the session so far. MannKind Corporation is a...
-
Pharma/Biotech Investor Spotlight - Recent Interview with Mr. Stephen M. Simes, President and CEO of BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
Thursday, May 12, 2011 - 10:52am | 1254Point Roberts, WA, LINCOLNSHIRE, Ill - May 12, 2011 - Investorideas.com, a leader in sector stock research for independent investors, releases the following updates for featured showcase biotech/pharma stock BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX). The company's President and CEO, Mr. Stephen...
-
Upgrades and Downgrades $INTC, CSCO, $HSGI, $SPY $V
Thursday, May 12, 2011 - 10:10am | 950Intel Corp (INTC) The Long- And The Short-Term Of It—Reiterate Buy Quick Stock Call — With the recent spate of good news (quarter results, multigate, dividend increase) driving appreciation, we see potential for ST profit taking in INTC, particularly in light of poor PC data points. But we view...
-
Human Genome Sciences Inc (HGSI) Trimming Benlysta's EU Pricing-CHMP Decision Expected Soon $HGSI
Thursday, May 12, 2011 - 9:43am | 1320Citibank anticipates the European CHMP will review GSK/HGSI's Benlysta's application for approval in lupus on either May 16-19 or June 20-23. Assuming a positive vote, actual approval should be within 60 days. While we expect approval, the risk/reward profile into this event is not favorable, in...
-
Biotech Investor Spotlight - Recent Interview with Mr. Stephen M. Simes, President and CEO of BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
Thursday, May 12, 2011 - 9:00am | 33Point Roberts, WA, LINCOLNSHIRE, Ill - May 12, 2011 – Investorideas.com, a leader in sector stock research for independent investors, releases the following updates for featured showcase biotech/pharma stock BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX).
-
Biotech Investor Spotlight - Recent Interview with Mr. Stephen M. Simes, President and CEO of BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
Thursday, May 12, 2011 - 9:00am | 33Point Roberts, WA, LINCOLNSHIRE, Ill - May 12, 2011 – Investorideas.com, a leader in sector stock research for independent investors, releases the following updates for featured showcase biotech/pharma stock BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX).
-
Biotech Investor Trading Alert; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Trades up 9.01 % on over 5 Million Shares Volume
Thursday, May 12, 2011 - 9:00am | 32Point Roberts, WA, LINCOLNSHIRE, Ill - May 13, 2011 – Investorideas.com, a leader in sector stock research for independent investors, issues a trading alert for specialty biotech/pharma stock, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX).
-
Biotech Investor Trading Alert; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Trades up 9.01 % on over 5 Million Shares Volume
Thursday, May 12, 2011 - 9:00am | 32Point Roberts, WA, LINCOLNSHIRE, Ill - May 13, 2011 – Investorideas.com, a leader in sector stock research for independent investors, issues a trading alert for specialty biotech/pharma stock, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX).
-
OXiGENE Announces Initiation of Phase 1 Trial of OXi4503 in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Thursday, May 12, 2011 - 8:00am | 114OXiGENE, Inc. (Nasdaq: OXGN) announced today that investigators at the University of Florida have initiated an investigator sponsored Phase 1 study of OXi4503 for the treatment of patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome. OXi4503 is a novel, next-generation...
-
Earnings Scheduled For May 12 (DRYS, JWN, AHII, KSS, DAR, NVDA, CACH, XIN, ACAT, BBOX, ESLR, CXPO, IRWD, CTFO, TREE, CYCC, CXDC)
Thursday, May 12, 2011 - 2:15am | 451DryShips Inc (NASDAQ: DRYS) is projected to post its Q1 EPS at $0.16 on revenue of $234.12 million. Nordstrom Inc (NYSE: JWN) is projected to report its Q1 EPS at $0.66 on revenue of $2.22 billion. Animal Health International Inc (NASDAQ: AHII) is expected to post its FQ3 EPS at $0.10 on revenue...
-
Stock Picks and Trade Ideas for Thursday, May 12
Wednesday, May 11, 2011 - 5:28pm | 2105( click to enlarge ) Shares of Rambus Inc. (NASDAQ:RMBS) are coming very near to its horizontal support of $18.77. Any close below this level will signal the next leg down has begun. Stop yourself out on any close below this level. Technically, the outlook for RMBS is relatively bearish....
-
Goldman Sachs Suggests Buying Calls on United Therapeutics (UTHR)
Wednesday, May 11, 2011 - 9:25am | 140Goldman Sachs is out with a research note this morning, where it suggests that traders buy calls on United Therapeutics Corporation (NASDAQ: UTHR) ahead of FREEDOM data. On March 9, Goldman recommended that investors buy the August $75 call for $8.39 (stock $68.69), and sell the Jan-12 $90 call...
-
Goldman Sachs Suggests Buying Calls on Vertex Pharmaceuticals (VRTX)
Wednesday, May 11, 2011 - 9:22am | 153Goldman Sachs is out with a research note this morning, where it suggests that traders buy calls on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) ahead of three key drug catalysts. Goldman Sachs SMid Cap Biotechnology Analyst, Terence Flynn, expects three upcoming catalysts to be positive...